Jan 10, 2022 | Press Releases
– Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications – – Initiation of both Phase 3 trials is expected...
Dec 20, 2021 | Press Releases
CUPERTINO, Calif., Dec. 20, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Nov 15, 2021 | Press Releases
– Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end – – Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with...
Sep 15, 2021 | Press Releases
CUPERTINO, Calif., Sept. 15, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Sep 2, 2021 | Press Releases
CUPERTINO, Calif., Sept. 02, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Aug 16, 2021 | Press Releases
-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4’21 -$35.8 Million in Cash as of June 30, 2021 CUPERTINO, Calif., Aug. 16,...
